Transforming Diagnosis and Treatment for Ulcerative Colitis and Atopic Dermatitis: IMI project ImmUniverse releases animated clip
ImmUniverse, the European research project investigating diagnosis and treatment options for patients living with ulcerative colitis and atopic dermatitis, has just released an animated video clip on the project’s approach and goals. The short animation aims to introduce the project in an easily accessible and entertaining format to the interested public. The clip is available on the ImmUniverse project website (https://immuniverse.eu/) and on YouTube (https://youtu.be/aeeOAX-A-wo). The project was launched in January 2020 with 26 international partners comprising academic institutions, pharmaceutical companies, patient organisations and specialised SMEs. Since then, the partners have worked persistently to make progress in developing new and innovative options to diagnose and treat the two immune-mediated inflammatory diseases ulcerative colitis and atopic dermatitis. The first year was strongly impacted by the challenging conditions of the COVID-19 pandemic. This meant that, in particular, certain clinical aspects of the project activities had to be postponed while the medical experts had to prioritise the care for and treatment of COVID patients. Nevertheless, important milestones were reached, such as the enrolment of patients in the clinical studies of the project and the set-up of common standards for sample inclusion, handling, extraction, transport and quality control. Further, ethics approval for in vitro studies was obtained to test the LIPUS- enabled gut liquid biopsy devices to allow identification of the OPTIMAL ultrasound parameters to trigger the desired bioeffect. For more information on the project please visit www.immuniverse.eu or follow @ImmUniverse_EU on Twitter.
Keywords
Ulcerative colitis, Atopic dermatitis, Immune-mediated inflammatory disease